Life science investors Syncona have committed $42.5 million to Beacon Therapeutics’ $170 million Series B financing round, bringing the total amount that Beacon has raised in funding to date to approximately $290 million. The funds will be used to support the continued clinical development of AGTC-501 for X-linked retinitis pigmentosa (XLRP) and to generate Phase […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!